CSC'S FIRSTDOC RECOGNIZED BY EMC AS A PREFERRED REGULATORY COMPLIANCE APPLICATION FOR LIFE SCIENCES INDUSTRY

CSC'S FIRSTDOC RECOGNIZED BY EMC AS A PREFERRED REGULATORY COMPLIANCE APPLICATION FOR LIFE SCIENCES INDUSTRY

 

CSC Solutions Built on EMC Documentum Enterprise Content Management Platform

FALLS CHURCH, Va., July 30 - CSC (NYSE: CSC) today announced an agreement with EMC Corporation to offer advanced compliance solutions to the life sciences industry. As part of the agreement, EMC will now offer CSC's FirstDoc as a preferred regulatory compliance application. FirstDoc, based on the EMC® Documentum® enterprise content management platform, has more than 100,000 users worldwide.

"Over the last decade, FirstDoc has consistently met the highest level of certification standards set by EMC, validating the design, performance and scalability of the application," said Jay DeWalt, vice president of Indirect & Solution Sales, Content Management and Archiving Division at EMC. "The latest release of FirstDoc, based on the Documentum 6.5 platform, demonstrates CSC's continued focus on innovation and on improving the end user's experience and productivity."    

"We're delighted that EMC recognizes FirstDoc as a preferred regulatory compliance application for the life sciences industry," said Nigel Whitehead, managing director of Life Sciences in CSC's Healthcare Group. "Documentum is an enterprise content management platform of choice for CSC's large and mid market customers, and we continue to design FirstDoc to take advantage of the platform's most robust features that now include access to FirstDoc and Documentum through SharePoint. We are committed to integrating FirstDoc with other complementary EMC products such as EMC Documentum Retention Policy Services, EMC Captiva InputAccel and EMC Documentum Content Transformation Services."

FirstDoc is designed to help life sciences companies with the enormous challenge and expense of meeting increased regulatory scrutiny and quality procedures. Specifically, it helps companies meet Part 11 of Title 21 of the Code of Federal Regulations (21 CFR Part 11) to ensure that electronic records and signatures are equivalent to those based on traditional paper based methods.

Earlier this year, CSC introduced new releases of its FirstDoc SharePoint Experience (SPX) and FirstDoc Collaborative Review Experience (CRX) content management solutions. In addition to being a cost-effective way to increase user access in a controlled SharePoint setting, SPX includes CSC's Secure Clinical Collaboration, which enhances controlled and cost effective collaboration between partner and sponsor. CRX offers controlled real-time co-authoring and edit capabilities with tools that augment the authoring process such as Microsoft Word, discussion threads, calendars, broadcast announcements and external Web site links. Other features include the ability to personalize SharePoint Web parts, or the building blocks of a SharePoint page, according to user role and content access privilege.

CSC's Healthcare Group, which serves healthcare providers, health plans, pharmaceutical and medical device manufacturers, and allied industries around the world, is a global leader in transforming the healthcare industry through the effective use of information to improve healthcare outcomes, decision-making and operating efficiency.

About CSC

CSC is a global leader in providing technology-enabled solutions and services through three primary lines of business. These include Business Solutions and Services, the Managed Services Sector and the North American Public Sector. CSC's advanced capabilities include systems design and integration, information technology and business process outsourcing, applications software development, Web and application hosting, mission support and management consulting. Headquartered in Falls Church, Va., CSC has approximately 92,000 employees and reported revenue of $16.74 billion for the 12 months ended April 3, 2009. For more information, visit the company's Web site at www.csc.com.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.